-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
The latest research results of Jimin Trust show that JMB2002 showed good biological activity and potential virus suppression effect in the Omi Keron pseudovirus neutralization experiment (Figure 2B)
One of the reasons for the enhanced transmission power of the Omi Keron mutant is that the receptor binding region of its spike protein and its receptor ACE2 are significantly enhanced compared to wild type.
JMB2002 has completed the domestic phase I clinical trial
JMB2002 completed the domestic phase I clinical study in June 2021, and its tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects reached the expected results
At present, Jimin Trust has completed the preparation of 2000 liters of JMB2002 clinical drugs, and the next step of clinical research can be initiated at any time